In a bed‑bound paraplegic patient with anemia and splenomegaly, what is the appropriate diagnostic work‑up and management?

Diagnostic Work-Up and Management of Bed-Bound Paraplegic Patient with Anemia and Splenomegaly

In a bed-bound paraplegic patient presenting with anemia and splenomegaly, the most critical priority is to rule out extramedullary hematopoiesis (EMH) causing spinal cord compression, as this represents a potentially reversible cause of paraplegia that requires urgent imaging and treatment.

Immediate Diagnostic Priorities

1. Establish the Cause of Paraplegia

The combination of paraplegia and splenomegaly with anemia strongly suggests EMH with spinal cord compression, particularly if the patient has an underlying hemoglobinopathy or myeloproliferative disorder 1, 2, 3.

Urgent imaging required:

• MRI of the thoracic spine with and without contrast – EMH most commonly compresses the cord at T2-T9 levels, with peak compression typically at T5-T6 2
• Look specifically for paraspinal masses causing cord compression

2. Comprehensive Anemia Work-Up

Initial laboratory evaluation:

• Complete blood count with peripheral smear (look for hemolysis, immature cells, macrocytosis)
• Reticulocyte count
• Ferritin (use 45 mg/dL cutoff for iron deficiency in anemic patients) 4
• Transferrin saturation
• LDH, haptoglobin, indirect and direct bilirubin (hemolysis markers) 5
• Direct antiglobulin test (Coombs)
• Hemoglobin electrophoresis (screen for thalassemia, sickle cell disease)

If ferritin is elevated or inflammatory state suspected:

• Transferrin saturation, soluble transferrin receptor, or reticulocyte hemoglobin equivalent for confirmation 4

3. Splenomegaly Evaluation

Imaging:

• Abdominal ultrasound or CT with contrast to measure spleen size and assess for:
  • Splenic infarcts
  • Extramedullary hematopoiesis 6
  • Portal hypertension
  • Hepatomegaly

Bone marrow examination with:

• Morphology and blast count
• Cytogenetics and FISH
• Flow cytometry
• Fibrosis grading 7, 8

This is essential to diagnose myeloproliferative neoplasms (particularly primary myelofibrosis), myelodysplastic syndromes, or hemoglobinopathies.

Specific Diagnostic Considerations

If Myeloproliferative Neoplasm Suspected:

• JAK2 V617F, CALR, and MPL mutations 9
• Peripheral blood for BCR-ABL to exclude chronic myeloid leukemia
• Consider ASXL1, SRSF2, EZH2, IDH1/2 mutations for prognostication 7

If Hemoglobinopathy Suspected:

• Hemoglobin electrophoresis
• Family history of anemia or splenomegaly
• History of transfusions

Management Algorithm

If EMH with Spinal Cord Compression is Confirmed:

First-line treatment: Radiotherapy 2, 3

• Low-dose radiation (0.1-1 Gy in 5-10 fractions) to the paraspinal EMH mass 10
• This is the treatment of choice and motor recovery is expected even in complete paraplegia 3
• Blood transfusions should be initiated concurrently to suppress ineffective erythropoiesis 2

Alternative/adjunctive therapies:

• Hydroxyurea to reduce hematopoietic drive 2
• Surgery reserved for cases with acute deterioration or radiotherapy failure

If Primary Myelofibrosis is Diagnosed:

For anemia (Hb <10 g/dL):

• First-line options (no clear superior agent, choose based on patient factors) 10, 9:
  • Corticosteroids (prednisone 0.5-1.0 mg/kg/day) – avoid if significant infection risk in bed-bound patient
  • Androgens (testosterone enanthate 400-600 mg weekly) – avoid if liver disease or prostate issues 9
  • Danazol 600 mg/day
  • Erythropoiesis-stimulating agents (limited efficacy if transfusion-dependent)
• If del(5q) present: Lenalidomide is preferred 10
• Response rates approximately 30-40% for single agents 10

For splenomegaly:

• Hydroxyurea as first-line (reduces spleen volume in ~40% of patients) 10
• Ruxolitinib for intermediate-2 or high-risk disease with symptomatic splenomegaly 9
• Splenic radiation (0.1-0.5 Gy in 5-10 fractions) provides transient relief but carries >10% mortality risk from cytopenia 10

If Thalassemia/Hemoglobinopathy:

• Regular transfusion program to suppress EMH
• Consider hydroxyurea
• Iron chelation if transfusion-dependent or evidence of iron overload 7

Critical Management Considerations for Bed-Bound Patients

Infection Prevention (Asplenic/Hyposplenic State):

Even with splenomegaly, functional hyposplenism may be present in myeloproliferative disorders:

• Immunizations 11:

  • Pneumococcal vaccine
  • Haemophilus influenzae type b
  • Meningococcal vaccine

• Antibiotic prophylaxis 11:

  • Penicillin V 250-500 mg twice daily (or erythromycin 250-500 mg daily if allergic)
  • Lifelong prophylaxis recommended, especially first 2 years

• Patient education: Keep supply of amoxicillin at home; seek immediate medical attention for fever 11

Thrombosis Prevention:

Bed-bound status plus myeloproliferative disorder creates extreme thrombotic risk:

• Pharmacologic VTE prophylaxis unless contraindicated by severe thrombocytopenia
• Monitor platelet count closely

Nutritional Support:

• Assess for iron deficiency despite splenomegaly (can coexist)
• If iron deficient: oral iron on empty stomach with vitamin C 500 mg, or IV iron if severe or malabsorption 4
• Nutritional consultation for cachexia if present in myelofibrosis

Common Pitfalls to Avoid

1. Missing reversible spinal cord compression from EMH – Always image the spine in paraplegic patients with hemoglobinopathies or myeloproliferative disorders
2. Assuming splenomegaly means adequate splenic function – Functional hyposplenism can coexist; provide infection prophylaxis 11
3. Using ferritin alone in inflammatory states – Ferritin can be falsely elevated; confirm with transferrin saturation or other markers 4
4. Delaying bone marrow examination – Essential for definitive diagnosis and prognostication in myeloproliferative/myelodysplastic disorders
5. Performing splenectomy without clear indication – High perioperative mortality (5-10%) in myelofibrosis; reserve for drug-refractory cases 10